Medical Developments International (MVP) H2 2024 earnings summary

Executive summary

• FY 2024 saw a 3% increase in group revenue to $33.2m, with improved margins, earnings, and cash flow, and group gross margin up 5 percentage points.

• Strategic priorities included margin improvement, Penthrox penetration in Australian hospitals, efficient European operations, and respiratory franchise growth in the U.S., with record in-market Penthrox volumes in Europe.

• Operational efficiency initiatives reduced costs by AUD 5 million, with further AUD 3–4 million in cost reductions expected in FY 2025.

• Penthrox volumes grew over 30% in Australian hospitals, and respiratory revenues in the U.S. rose 37%.

• The MAGPIE pediatric study supports regulatory submissions to expand Penthrox's age indication in Europe.

Financial highlights

• Gross margin improved to 74%, mainly due to higher pricing in Australia.

• Underlying EBIT loss improved by AUD 6.6 million to $(11.6)m; free cash flow improved by AUD 10.2 million.

• Net loss after tax was AUD 41 million, impacted by non-cash asset impairments and derecognition of tax losses.

• Free cash flow improved by AUD 10.2 million; cash at period end was AUD 9.7 million, rising to AUD 19 million post-capital raise.

• Pain Management segment revenue grew 4% to $21.3m, while Respiratory segment revenue rose 1% to $11.9m.

Outlook and guidance

• FY 2025 will focus on further margin improvement, targeting an additional AUD 3–4 million in earnings benefits.

• Positive operating cash flows are expected by the end of FY 2025.

• Underlying EBIT in FY 2025 is expected to be strongly improved, driven by higher Penthrox prices and operational efficiencies.

• CapEx for FY 2025 is projected at around AUD 1.5–2 million.